| Code | CSB-RA004960MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to the reference antibody described in US10815306B2, targeting CD81, a member of the tetraspanin superfamily. CD81 is a widely expressed cell surface protein that plays critical roles in cellular processes including cell adhesion, migration, and signal transduction. It functions as an essential component of the CD19/CD21/CD81 B-cell co-receptor complex, modulating B-cell activation and antibody responses. CD81 serves as a key entry receptor for hepatitis C virus and has been implicated in various pathological conditions including viral infections, cancer progression, and immune dysregulation. The protein's involvement in tumor cell motility and metastasis makes it a relevant target in oncology research.
This biosimilar antibody replicates the binding characteristics of the reference antibody disclosed in patent US10815306B2, providing researchers with a reliable tool for investigating CD81-mediated biological processes. It is suitable for studies examining tetraspanin function, B-cell biology, viral pathogenesis, and tumor microenvironment interactions. The antibody enables exploration of CD81's therapeutic potential across multiple disease contexts.
There are currently no reviews for this product.